Walk Into ASCO 2026 With Momentum on Your Side

The American Society of Clinical Oncology (ASCO) Annual Meeting is always a big moment for science and for how oncology stories take shape. But the preparation and planning can feel daunting. With thousands of abstracts dropping at once, attendees are immediately fielding questions from reporters, investors, and advocacy partners about what it all means. The Spectrum Signal is our momentum-driving answer to that moment. 

At Spectrum, we’ve taken a platform-wide look at the ASCO 2026 program to help teams understand what the abstracts are signaling, how media and key influencers are likely to cover the meeting, and where the narratives that truly cut through will come from. Because success at ASCO doesn’t come from volume, it comes from preparation and clarity.

What the Science Is Telling Us 

A review of program tracks and late‑breaking titles shows a continued shift away from early‑stage, single‑agent stories toward scalable platforms and combination strategies tailored to specific patient populations. Expect more data in earlier‑line and perioperative settings, growing emphasis on tumor‑agnostic and antigen‑driven approaches, and fewer standalone checkpoint inhibitor headlines. 

For communicators and commercial teams, this evolution raises the stakes. Media, investors, and clinicians are increasingly demanding clear differentiation, realistic assessments of benefit versus risk, and a precise understanding of how a program fits within a crowded and competitive oncology landscape. 

The Themes That Will Shape the Conversation 

Based on the full ASCO 2026 program, we’re closely tracking 10 meeting‑wide themes likely to drive headlines, investor questions, and competitive narratives after the meeting.  

Among them: 

1. ADCs keep widening their footprint. New targets (e.g., CDH6, integrin-6) and increasingly strategic combinations are expanding the ADC story across tumor types and into earlier lines – while toxicity management and sequencing questions become part of the headline, not a footnote. 
2. Bispecifics are moving beyond hematology. Momentum continues in blood cancers, but the meeting also reflects a real push into solid tumors, with more diversity in format (checkpoint pairings, cytokine-biased approaches, T-cell engagers) and a more competitive set of players. 
3. TCR-engineered and adoptive cell therapies are getting more “real world.” Programs targeting antigens like PRAME are broadening cohorts and sharpening patient selection logic – an important step toward proving these approaches can be repeatable outside of highly specialized centers. 

Explore the remaining seven themes — and a pre‑ASCO planning cheat sheet — on our ASCO resource page.

How the ASCO Story Will Be Told 

Media coverage at ASCO 2026 will likely concentrate around three modality stories: ADCs, bispecifics (especially in solid tumors), and radioligand therapy. But keep in mind, the scrutiny floor has been raised. Companies will need to plan more than ever for a gauntlet of digital-native clinicians and specialized reporters who can deconstruct a clinical trial protocol in a 280-character thread before the first presentation even ends. These folks will be quick to lend their perspective on trial design, patient selection, endpoint relevance, and toxicity management.  

The teams that break through are the ones that do the fundamentals exceptionally well:  

• explain the unmet need plainly  

• articulate why the data is credible 

• anticipate skepticism 

• connect their results to the questions the field is already debating — sequencing, combinations, operational feasibility, and meaningful patient impact 

Get Fully Prepared 

ASCO momentum is built before the meeting begins. If you’re looking for deeper insights, strategic context, and a practical pre‑ASCO planning framework, explore our full Spectrum Signal: ASCO 2026 resource page and request access to learn more.